Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Moderna's RSV vaccine gets Breakthrough Therapy status
07:26am, Monday, 30'th Jan 2023
Moderna Inc. MRNA, -2.01% said Monday that the Food and Drug Administration granted the company's experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it p
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
07:00am, Sunday, 29'th Jan 2023
Two of these stocks have what it takes to rebound and deliver lasting gains.
Mergers and Acquisitions in 2023 Off To A Strong Start
08:17am, Friday, 27'th Jan 2023
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $
Could This RSV News Make Moderna a Hot Buy Again?
10:00am, Wednesday, 25'th Jan 2023
The company could soon have a new vaccine bringing in revenue.
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
06:04am, Saturday, 21'st Jan 2023
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
Moderna and Pfizer Race to Release RSV Vaccines
10:14am, Friday, 20'th Jan 2023
Two of the largest vaccine producers have engaged in the rapid development of RSV vaccines, here's how the companies are tracking so far.
GSK faces new RSV vaccine competitor after Moderna data, says Barclays
03:55am, Friday, 20'th Jan 2023
GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. “Moderna's efficacy data looks in
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
01:41pm, Thursday, 19'th Jan 2023
Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Crack
Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?
04:31am, Thursday, 19'th Jan 2023
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Stocks moving after the closing bell: Kraft Heinz, Microsoft, Party City, Celsius
06:00pm, Wednesday, 18'th Jan 2023
Yahoo Finance Live anchor Jared Blikre breaks down the performance of several trending stocks following Wednesday's closing bell.
Moderna's mRNA RSV vaccine propels stock gains
02:07pm, Wednesday, 18'th Jan 2023
Michael Yee, managing director at Jefferies, joins 'The Exchange' to discuss what's driving Moderna's stock activity, the unique mRNA technology behind the company's RSV vaccine and portfolio opportun
Moderna CEO on Vaccines, Mutation Risk
12:44pm, Wednesday, 18'th Jan 2023
Moderna CEO Stephane Bancel says the current risk of virus mutations out of China are not high. He speaks to Bloomberg from the World Economic Forum in Davos.
Moderna is the latest company to produce a promising RSV vaccine
12:23pm, Wednesday, 18'th Jan 2023
Moderna's disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of n
Moderna Finds Life After Covid-19
12:21pm, Wednesday, 18'th Jan 2023
Even as Covid-19 turned Moderna into a biotech giant, the debate on Wall Street over its prospects has continued to rage.
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
12:03pm, Wednesday, 18'th Jan 2023
Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
